GnRH antagonists for patients with uterine fibroids
GnRH antagonists potential to become a viable alternative to surgery for the long-term management of UF
GnRH antagonists have been shown to have up to 90% efficacy at week 52
Important differences between available GnRH antagonists
Potential vasomotor symptoms (VMS) associated with GnRH antagonists
Potential bone mineral density effects associated with GnRH antagonists
Addition of add-back therapy to a GnRH antagonist
There may be important differences in the effect different GnRH antagonists can have on bone
Not all GnRH antagonists have been formulated in the same way
UF affects Black women more commonly
Pharmacokinetic parameters can vary when looking at certain populations
GnRH antagonists have important differences in their PK profiles
